<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000512.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;div class="dc:title"&gt;Benson2014 - FAAH inhibitors for the treatment of osteoarthritic pain&lt;/div&gt;
  &lt;div class="dc:description"&gt;
    &lt;p&gt;Evaluation of fatty acid amide hydrolase (FAAH) as a target for osteoarthritic pain in humans, using an integrated systems pharmacology model.&lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:provenance"&gt;
    &lt;p&gt;The SBML version of the model is obtained from the supplementary material of the corresponding paper (see below).&lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:bibliographicCitation"&gt;
    &lt;p&gt;This model is described in the article:&lt;/p&gt;
    &lt;div class="bibo:title"&gt;
      &lt;a href="http://identifiers.org/pubmed/24429592" title="Access to this publication"&gt;A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain.&lt;/a&gt;
    &lt;/div&gt;
    &lt;div class="bibo:authorList"&gt;Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH.&lt;/div&gt;
    &lt;div class="bibo:Journal"&gt;CPT Pharmacometrics Syst Pharmacol. 2014 Jan 15;3:e91.&lt;/div&gt;
    &lt;p&gt;Abstract:&lt;/p&gt;
    &lt;div class="bibo:abstract"&gt;
      &lt;p&gt;The level of the endocannabinoid anandamide is controlled by fatty acid amide hydrolase (FAAH). In 2011, PF-04457845, an irreversible inhibitor of FAAH, was progressed to phase II clinical trials for osteoarthritic pain. This article discusses a prospective, integrated systems pharmacology model evaluation of FAAH as a target for pain in humans, using physiologically based pharmacokinetic and systems biology approaches. The model integrated physiological compartments; endocannabinoid production, degradation, and disposition data; PF-04457845 pharmacokinetics and pharmacodynamics, and cannabinoid receptor CB1-binding kinetics. The modeling identified clear gaps in our understanding and highlighted key risks going forward, in particular relating to whether methods are in place to demonstrate target engagement and pharmacological effect. The value of this modeling exercise will be discussed in detail and in the context of the clinical phase II data, together with recommendations to enable optimal future evaluation of FAAH inhibitors.&lt;/p&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class="dc:publisher"&gt;
    &lt;p&gt;This model is hosted on        &lt;a href="http://www.ebi.ac.uk/biomodels/"&gt;BioModels Database&lt;/a&gt;
            and identified
by:        &lt;a href="http://identifiers.org/biomodels.db/MODEL1402030000"&gt;MODEL1402030000&lt;/a&gt;
            .        &lt;/p&gt;
    &lt;p&gt;To cite BioModels Database, please use:        &lt;a href="http://identifiers.org/pubmed/20587024" title="Latest BioModels Database publication"&gt;BioModels Database: An enhanced, curated and annotated resource
for published quantitative kinetic models&lt;/a&gt;
            .        &lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:license"&gt;
    &lt;p&gt;To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to the public
domain worldwide. Please refer to        &lt;a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication"&gt;CC0 Public Domain
Dedication&lt;/a&gt;
            for more information.        &lt;/p&gt;
  &lt;/div&gt;
&lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain</ns3:title>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns4:identifier xmlns:ns4="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1038/psp.2013.72"/>
    <ns5:label xmlns:ns5="http://www.w3.org/2000/01/rdf-schema#">N Benson, E Metelkin, O Demin, GL Li, D Nichols &amp; PH van der Graaf. A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain. CPT: Pharmacometrics &amp;amp; Systems Pharmacology 3, 1 (2014).</ns5:label>
  </rdf:Description>
</rdf:RDF>

